Clinical study of reattribution-cognitive-pharmacy model in the treatment for irritable bowel syndrome
10.3760/cma.j.issn.1674-6554.2010.12.005
- VernacularTitle:重归因-认知-药物模式治疗肠易激综合征的临床疗效研究
- Author:
Jianxin CAO
;
Yulan WANG
;
Xuexia REN
;
Guoyan ZHU
- Publication Type:Journal Article
- Keywords:
Irritable bowel syndrome;
Treatment;
Reattribution-cognitive-pharmacy;
Model
- From:
Chinese Journal of Behavioral Medicine and Brain Science
2010;19(12):1069-1070
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate clinical effect of reattribution-cognitive-pharmacy model (RCPM) in the treatment for irritable bowel syndrome(IBS). Methods 125 subjects with diarrhea predominant irritable bowel syndrome (IBS-D) were divided into two groups randomly. 62 patients in group A were treated with 10 ～ 20 mg of paroxetine without any other medication or psychological interview and 63 patients in group B received RCPM with interviewing once a week for 6 sessions and took 10 ～ 20 mg of paroxetine in the same way as group A after a week. The effect was evaluated at the end of 4 weeks and 12 weeks by a questionnaire. Results At the end of 4 weeks,29 patients in group A reported a reduction in abdominal pain,and 28 reported a reduction in stool frequency ,and 12 patients stopped taking paroxetine because of worrying about those side effect . In group B 48 reported a reduction in abdominal pain ,and 42 reported a reduction in stool frequency ,and 3 patients stopped taking paroxetine. At the end of 12 weeks,36 patients in group A reported a reduction in abdominal pain ,and 30 reported a reduction in stool frequency,and 14 patients stopped taking paroxetine because of worry about those side effect. In group B,54 cases reported a reduction in abdominal pain,and 45 reported a reduction in stool frequency,and 5 patients stopped taking paroxetine because of no obvious improvement. Conclusion RCPM can alleviate the abdominal pain and bowl movement frequency of IBS-D,and it seems better than paroxetine treatment alone. RCPM can improve compliance of paroxetine in patients with IBS-D.
